GlassScriptPhysician profile
Krystal Umfleet
NPI 1679931968
$11,438.64
in general payments reported to CMS, 2019-2025
45 companies · $2,460 in 2025
The $2,460 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,054 · 2022: $2,083 · 2023: $2,716 · 2024: $3,125 · 2025: $2,460.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,182 · Education: $119.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,182.31 |
| Education | $119.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,910.33 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,836.19 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,588.70 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $1,063.47 | 2022-2025 | Stelara, Tremfya, Simponi Aria |
| Qol Medical, LLC | $667.78 | 2021-2025 | Sucraid, Sucraid |
| Ardelyx, INC. | $435.43 | 2022-2025 | Ibsrela |
| Celgene Corporation | $373.51 | 2022-2024 | Zeposia |
| Gilead Sciences, INC. | $269.48 | 2022-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $259.39 | 2022-2023 | Ocaliva |
| Lucid Diagnostics INC. | $237.26 | 2021-2025 | |
| Nestle Healthcare Nutrition INC. | $235.01 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $221.28 | 2021-2024 | Dificid |
| Daiichi Sankyo INC. | $201.89 | 2021-2025 | Injectafer |
| Genzyme Corporation | $198.65 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $190.80 | 2023-2025 | Rebyota |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krystal Umfleet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.